About Blueberry Therapeutics
Blueberry Therapeutics is a company based in Alderley Edge (United Kingdom) founded in 2011 by Michael John Davies. Blueberry Therapeutics has raised $23.77 million across 5 funding rounds from investors including Maven Capital Partners, China Medical System and Medical Incubator Japan. The company has 16 employees as of May 31, 2021. Blueberry Therapeutics offers products and services including Nanopolymer Drug Delivery System and Therapy for Onychomycosis. Blueberry Therapeutics operates in a competitive market with competitors including Sirnaomics, Acorda, Liquidia, Genedit and NanoSyrinx, among others.
- Headquarter Alderley Edge, United Kingdom
- Employees 16 as on 31 May, 2021
- Founders Michael John Davies
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Blueberry Therapeutics Limited
- Date of Incorporation 08 Nov, 2011
- Jurisdiction MACCLESFIELD, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
$615.53 K (USD)0as on May 31, 2019
-
Net Profit
-$3.76 M (USD)-37as on May 31, 2022
-
EBITDA
-$4.68 M (USD)1as on May 31, 2022
-
Total Equity Funding
$23.77 M (USD)
in 5 rounds
-
Latest Funding Round
$1.06 M (USD), Debt – Conventional
Jun 08, 2021
-
Investors
Maven Capital Partners
& 5 more
-
Employee Count
16
as on May 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blueberry Therapeutics
Blueberry Therapeutics offers a comprehensive portfolio of products and services, including Nanopolymer Drug Delivery System and Therapy for Onychomycosis.
Advanced system for topical drug delivery to treat skin disorders effectively.
Nanomedicine-based treatment for fungal nail infections and related conditions.
People of Blueberry Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Blueberry Therapeutics
Blueberry Therapeutics has successfully raised a total of $23.77M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $1.06 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Blueberry Therapeutics
Blueberry Therapeutics has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Maven Capital Partners, China Medical System and Medical Incubator Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Investment in innovative healthcare startups is facilitated by this company.
|
Locked | Locked | Locked | |
|
Venture capital funds are managed for life sciences and growth businesses.
|
Locked | Locked | Locked |
Investor details for Blueberry Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Blueberry Therapeutics
Investment portfolio details for Blueberry Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Blueberry Therapeutics
Detailed financials for Blueberry Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Blueberry Therapeutics Comparisons
Peer comparison for Blueberry Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Blueberry Therapeutics
Blueberry Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Acorda, Liquidia, Genedit and NanoSyrinx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Engaged in the development and commercialization of therapies that improve neurological function.
|
|
| Locked | Locked | Locked |
Engineered particles & films for life and material sciences applications
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Drug delivery systems to cell interiors are developed via nanosyringes.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
Detailed competitors of Blueberry Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Blueberry Therapeutics
Complete news archive for Blueberry Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blueberry Therapeutics
Blueberry Therapeutics was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Blueberry Therapeutics is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge, Cheshire, United Kingdom.
Blueberry Therapeutics is a funded company, having raised a total of $23.77M across 5 funding rounds to date.
As of May 31, 2021, the latest employee count at Blueberry Therapeutics is 16.
Annual revenue of Blueberry Therapeutics is $615.53K as on May 31, 2019.
Blueberry Therapeutics is a modern drug discovery and development company specializing in polymer-drug delivery. Its nanopolymer drug delivery system self-assembles with both small and large molecules (e.g. proteins, peptides, and nucleic acids) and packages them into nanoparticles. These nanoparticles enhance cellular delivery into both mammalian and bacterial cells. It is developing OTC products to treat Onychomycosis (fungal nail infection), tinea pedis (athletes foot), acne, and acute wounds. Also developing prescription peptide therapeutics to treat Atopic Dermatitis, Inflammatory Bowel Disease.
Blueberry Therapeutics's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
Blueberry Therapeutics offers Nanopolymer Drug Delivery System and Therapy for Onychomycosis.
Blueberry Therapeutics has 6 investors. Key investors include Maven Capital Partners, China Medical System, Medical Incubator Japan, Omar Ibrahimi, and InClin.